Healthcare systems have been severely impacted by the COVID-19 pandemic, both in terms of workload and the resources, what has impacted patients who require treatment for their chronic wounds? Amputation rates have tripled during this period, suggesting that chronic wound patients are not able to access their regular care channels, to receive care for their wounds, especially when in need of surgical debridements to remove biofilm and the infection inside it.
DEBRICHEM® takes an innovative approach to chemical debridement of non-healing wounds. Due to its uncomplicated use, DEBRICHEM® could be highly beneficial during the COVID-19 pandemic or similar situations. This novel acidic gel addresses the biofilm and the pathogens inside the wound bed, with a single treatment that is only applied once for 60 seconds and does not need a sterile environment such as a surgery room. DEBRICHEM® is launching across Europe, since CE-certification earlier this year.
Read more about the advantages of using DEBRICHEM® in this article in Health Europa